EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy

Tiziano Barbui iD, Alessandra Carobbio, Paola Guglielmelli iD, Arianna Ghirardi, Francesca Fenili, Giuseppe Gaetano Loscocco iD, Valerio De Stefano iD, Francesco Ramundo, Maria Chiara Finazzi, Alessandro Rambaldi, Alessandro M Vannucchi iD

British Journal of Haematology · 2024-12 · 205 (6) · 2287-2294

DOI: 10.1111/bjh.19813 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, online erschienen am 07.10.2024. Verfasst von Tiziano Barbui und 10 weiteren Autor:innen. Beteiligte Einrichtung: FROM, Fondazione per la Ricerca Ospedale di Bergamo ETS, Bergamo, Italy. Hauptthemen laut MEDLINE: Interferon alpha-2, Interferon-alpha, Janus Kinase 2, Lymphocytes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: AOP Health, Fondazione AIRC per la Ricerca sul Cancro ETS, MYeloid NEoplasms Research Venture AIRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated the effect of Ropeginterferon alfa‐2b (Ropeg) versus phlebotomy‐only (Phl‐O) on the neutrophil‐to‐lymphocyte ratio (NLR) in 126 patients randomized in the low‐polycythaemia vera (PV) phase II trial. Patients with a baseline NLR ≥3.5 vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon alpha-2Interferon-alphaJanus Kinase 2LymphocytesNeutrophilsPolycythemia VeraPolyethylene GlycolsAdultAgedFemaleHumansMaleMiddle AgedLeukocyte CountRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

JAK2 VAFRopeginterferonneutrophil/lymphocyte ratioquality of lifetreatment response

Substanzen

Interferon alpha-2Interferon-alphaJAK2 protein, humanJanus Kinase 2peginterferon alfa-2bPolyethylene GlycolsRecombinant Proteins

Autor:innen und Institutionen

  • FROM, Fondazione per la Ricerca Ospedale di Bergamo ETS, Bergamo, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Materno-Infantili e dell'Adulto, Università di Modena-Reggio Emilia, Modena, Italy.
  • CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
  • Institute of Hematology, Catholic University, Rome, Italy.
  • Fondazione Policlinico Universitario A. Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Divisione di Ematologia, ASST Papa Giovanni XXIII, Bergamo, Italy.

ORCID-Profile: Tiziano Barbui, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Valerio De Stefano, Alessandro M Vannucchi

Förderung

  • AOP Health
  • Fondazione AIRC per la Ricerca sul Cancro ETS
  • MYeloid NEoplasms Research Venture AIRC
  • BCC Milano

Zitieren

APA

Barbui, T., Carobbio, A., Guglielmelli, P., Ghirardi, A., Fenili, F., Loscocco, G. G., De Stefano, V., Ramundo, F., Finazzi, M. C., Rambaldi, A., & Vannucchi, A. M. (2024). Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy. British Journal of Haematology, 205(6), 2287-2294. https://doi.org/10.1111/bjh.19813

Vancouver

Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, et al. Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy. British Journal of Haematology. 2024;205(6):2287-2294. doi:10.1111/bjh.19813

BibTeX
@article{Barbui2024,
  author = {Barbui, Tiziano and Carobbio, Alessandra and Guglielmelli, Paola and Ghirardi, Arianna and Fenili, Francesca and Loscocco, Giuseppe Gaetano and De Stefano, Valerio and Ramundo, Francesco and Finazzi, Maria Chiara and Rambaldi, Alessandro and Vannucchi, Alessandro M},
  title = {Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {6},
  pages = {2287--2294},
  doi = {10.1111/bjh.19813}
}
Kostenlos starten →